We have isolated a cardiomyogenic cell line (CMG cell) from murine bone marrow mesenchymal stem cells. The cells showed a fibroblast-like morphology, but the morphology changed after 5-azacytidine exposure. They began spontaneous beating after 2 weeks, and expressed ANP and BNP. Electron microscopy revealed a cardiomyocytelike ultrastructure. These cells had several types of action potentials; sinus node-like and ventricular cell-like action potentials. The isoform of contractile protein genes indicated that their muscle phenotype was similar to fetal ventricular cardiomyocytes. They expressed α 1A , α 1B , α 1D , β 1 , and β 2 adrenergic and M 1 and M 2 muscarinic receptors. Stimulation with phenylephrine, isoproterenol and carbachol increased ERK phosphorylation and second messengers. Isoproterenol increased the beating rate, which was blocked with CGP20712A (β 1 -selective blocker). These findings indicated that cell transplantation therapy for the patients with heart failure might possibly be achieved using the regenerated cardiomyocytes from autologous bone marrow cells in the near future.
Introduction
Although heart transplantation is the ultimate therapy for the treatment of severe heart failure, it has not been widely examined due to the lack of donor hearts. The inadequate supply of donor hearts is often a major problem everywhere in the world. As a result, the current challenge in cardiology is how to reserve pump failure by cell transplantation or regenerative medicine. Recent studies have shown that transplanted fetal cardiomyocytes can survive in heart scar tissue and that the transplanted cells limit scar expansion and prevent post-infarction heart failure. Transplantation of cultured cardiomyocytes into the damaged myocardium has been proposed as a future method of treating heart failure (Soonpaa et al., 1997; Delcarpio & Claycomb, 1997) . This revolutionary concept remains unfeasible in clinical settings because of the difficulty of obtaining donor fetal hearts. Thus, a cardiomyogenic cell line has long been awaited, and such a line might be capable of substituting for fetal cardiomyocytes in this therapy.
Various studies have demonstrated that cardiomyocytes can differentiate from multipotent stem cells such as embryonic stem (ES) cells (Wobus et al., 1991) and embryonic carcinoma (EC) cells (Wobus et al., 1994) . ES cells are an attractive cell source in regenerative medicine, but the recipients must take immunodepressant drugs throughout their lives because the transplanted ES cells are allogeneic. Use of these reagents impairs the quality of life of the recipients, and transplantation of undifferentiated ES cells often causes teratocarcinoma. In addition, the establishment of human ES cells involves ethical problems and is not allowed in every country. Because of these circumstances, the regeneration of cardiomyocytes from adult autologous stem cells has been awaited.
Recent reports have demonstrated the existence of pluripotent stem cells in adult tissues. Roy et al. (2000) reported the existence of neural stem cells in the brain that can differentiate into neurons, oligodendrocytes, and astrocytes in vitro. Marrow stromal cells have been shown to possess many characteristics of mesenchymal stem cells (Prockop, 1997) , and pluripotent progenitor marrow stromal cells can differentiate into various types of cell types, including osteoblasts (Rickard et al., 1994; Friedenstein et al., 1987) , myocytes (Ferrari et al., 1998) , adipocytes, tenocytes, and chondroblasts (Ashton et al., 1980) . We recently reported the differentiation of mesenchymal stem cells into cardiomyocytes after exposure to 5-azacytidine and the establishment of cell line CMG (cardiomyogenic) that differentiates into cardiomyocytes in vitro (Makino et al., 1999) . CMG cells exhibit spontaneous beating and express atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), and they may provide a useful and powerful tool for cardiomyocyte transplantation after further characterization of their cardiomyocyte phenotype.
This paper describes the characteristics of bone marrow-derived regenerated cardiomyocytes and discusses the possibility of using them for cardiovascular tissue engineering. The expression and function of adrenergic and muscarinic receptors in CMG cells is also described, because these receptors play a critical role in modulating cardiac function (Hakuno et al., 2002) .
Mesenchymal marrow stem cells as a possible source of cardiomyocytes: The cardiomyogenic (CMG) cell? Figure 1 shows the classification of the stem cell system of adults (Fukuda, 2001) . Bone marrow stromal cells were previously used as a feeder layer to culture hematopoietic stem cells, and are known to be of mesodermal origin and produce various cytokines and growth factors. In late 1990's, a number of papers reported that bone marrow stromal cells contain multipotent stem cells for non-hematopoietic tissues, called 'marrow mesenchymal stem cells', that could differentiate into osteoblasts, chondroblasts, and adipocytes. All of these cells were known to be of mesodermal origin. If mesenchymal stem cells are multipotent, we hypothesized that they might have the ability to differentiate into cardiomyocytes and instituted this study. We also thought that bone marrow cells could be obtained from patients themselves and that autologous cells would not be rejected after cell transplantation.
Method of establishing bone-marrow derived cardiomyocytes
Female C3H/He mice were anesthetized with ether, their femora were excised, and primary culture of the marrow cells was performed according to Dexter's method. Cells were cultured in Iscove's modified Dulbecco's medium (IMDM) supplemented with 20% fetal bovine serum and penicillin (100 µg ml −1 )/streptomycin (250 ng ml −1 )/amphotericin B at 33 • C in humid air containing 5% CO 2 . After a series of passages, immortalized cells were obtained by frequent subculture for more than 4 months. Cell lines from different dishes were subcloned by limiting dilution. To induce cell differentiation, cells were treated with 3 µmol l −1 of 5-azacytidine for 24 hr. Subclones that included spontaneously beating cells were screened by microscopic observation (first screening), and cells surrounding spontaneous beating cells were subcloned with cloning syringes. Subcloned cells were maintained, exposed to 5-azacytidine again for 24 hr, and clones that showed spontaneous beating most frequently were screened (second screening). The clonal cell line thus obtained was named the CMG cell.
As a result of repeated rounds of limiting dilution, we succeeded in isolating 192 single clones, several of which differentiated into cardiomyocytes and showed spontaneous beating. The experiments were reproducible, but the percentage of cells that differentiated into cardiomyocyte differentiation was specific to each clones. Phase-contrast photography and/or immunostaining with anti-sarcomeric myosin antibodies were used to identify the morphological changes in the CMG cells. CMG cells showed a fibroblast-like morphology before 5-azacytidine treatment (0 week), and this phenotype was retained through repeated subculturing under non-stimulating conditions. After 5-azacytidine treatment, however, the morphology of the cells gradually changed (Figure 2 ). Approximately 10-30% of the CMG cells gradually increased in size at 1 week, and they formed ball-like appearance, or had lengthened in one direction to exhibit a stick-like morphology. Most of the other non-myocytes had an adipocyte-like appearance.
Regenerated cardiomyocytes display a fetal ventricular phenotype
Various cardiac contractile protein isoforms are differentially expressed in cardiomyocytes at different developmental stages and in different chambers. At around the time of birth there is a developmental switch in the ventricular muscle of small mammals from expression of β-myosin heavy chain (MHC), which is the predominant fetal form, to expression of α-MHC. There is also a developmental switch from expression of α-skeletal actin, which is the predominant fetal and neonatal form, to that of α-cardiac actin, the predominant adult form. We investigated the contractile protein isoforms of bone marrow-derived CMG cells to characterize their phenotype as cardiomyocytes. Table 1 summarizes the results. Fetal, neonatal, and adult ventricle and atrium were used as controls (Fukuda, 2001) . Expression of both α-and β-MHC was detected in differentiated CMG cells by RT-PCR, but β-MHC expression was overwhelmingly greater than that of α-MHC. CMG cells expressed both α-cardiac and α-skeletal actin, but the α-skeletal actin gene was expressed at markedly higher levels than the α-cardiac actin gene. Interestingly, CMG cells expressed the myosin light chain (MLC)-2v gene, but not the MLC-2a gene. MLC-2v is specifically expressed in ventricular cells, while MLC-2a is specifically expressed in atrial cells. Skeletal muscle cells do not express either α-MHC or MLC-2v. These results indicated that differentiated CMG cells possess the specific phenotype of the fetal ventricular cardiomyocytes (Makino et al., 1999) .
Developmental stage of undifferentiated and differentiated CMG cells
Various cardiac specific transcription factors have been cloned, and their genes are serially expressed in the developing heart during myogenesis and morphogenesis. Figure 3 shows the time course of the expression of cardiomyocyte-specific transcription factors in fetal developing heart and CMG cells. The genes coding Nkx2.5 (Linnets et al., 1993) (homeobox type transcription factor specifically expressed beginning in the early developing heart), GATA4 (Arceci et al., 1993 ) (GATA-motif-binding Zinc finger type transcription factor expressed beginning in the early stage developing heart), HAND1/2 (basic HLH type transcription factor expressed in the heart and autonomic nervous system), and MEF2-B/C (Edmondson et al., 1994 ) (muscle enhancement factor: a MADS box family transcription factor expressed in the myocytes) were expressed in the early stage of heart development, and MEF2A and MEF2-D in the middle stage. The CMG cells already expressed GATA4, TEF-1 (Chen et al., 1994 ) (transcription enhancement factor 2), Nkx2.5, HAND, and MEF2-C before exposure to 5-azacytidine, and they expressed MEF2-A and MEF2-D after exposure to 5-azacytidine. This pattern of gene expression in CMG cells was similar to that of developing cardiomyocytes in vivo (Makino et al., 1999) , and indicated that the developmental stage of the undifferentiated CMG cells is close to that of cardiomyoblasts or the early stages of heart development. We estimated that the stage of differentiation of the CMG cells lies between the cardiomyocyte-progenitor stage and the differentiated cardiomyocyte stage.
Serial changes in action potential shape in CMG cells simulate those of fetal ventricular cardiomyocytes in vivo
CMG cells exhibit at least two types of distinguishable morphological action potentials: sinus-node-like potentials ( Figure 4a ) and ventricular myocyte-like potentials ( Figure 4b ) (Makino et al., 1999) . The cardiomyocyte-like action potential recorded from these spontaneous beating cells is characterized by (1) a relatively long action potential duration or plateau, (2) a relatively shallow resting membrane potential, and (3) a pacemaker-like late diastolic slow depolarization. Peak-and-dome-like morphology was observed in ventricular-myocyte-like cells. Figure 4c shows the time course of the percentages of the sinus node-like and ventricular-myocyte-like action potentials. All action potentials recorded from CMG cells until 3 weeks were sinus-node-like action potential. The ventricular-myocyte-like action potentials were first recorded after 4 weeks, and their percentage gradually increased thereafter. The observation of several distinct patterns of action potential in CMG cells may reflect different developmental stages. Yasui et al. studied action potentials and the occurrence of one of the pacemaker currents, I(f), by the whole-cell voltage and current-clamp technique at the stage when a regular heartbeat is first established (9.5 days post coitum) and at 1 day before birth (Yasui et al., 2001 ). They showed a prominent I(f) in mouse embryonic ventricles in the early stage, and that it decreased by 82% before birth in tandem with the loss of regular spontaneous activity by the ventricular cells. They concluded that the I(f) current of the sinus node type is present in early embryonic mouse ventricular cells. Loss of the I(f) current during the second half of embryonic development is associated with a tendency for the ventricle to lose pacemaker potency. Our findings in CMG cells may reflect the developmental changes in the action potentials that occur in embryonic ventricular cardiomyocytes.
Expression and function of α 1 -adrenergic receptors in CMG cells
In the heart in vivo, α and β adrenergic receptors play a key role in modulating cardiac hypertrophy and cardiac function, such as heart rate, contractility, and conduction velocity. CMG cells expressed all the α 1 receptor subtypes (α 1A , α 1B , and α 1D ) before 5-azacytidine exposure (Figure 5a ) (Hakuno et al., 2002) , and their expression in undifferentiated CMG cells may be explained by their ubiquitous or wide expression in vivo (Alonso-Llamazares et al., 1995) . A low level of expression of α 1A was observed before 5-azacytidine exposure, and it increased markedly after exposure. Expression of α 1B was unaffected by 5-azacytidine. A high level of expression of α 1D was detected before 5-azacytidine exposure, but it decreased considerably after exposure. This tran- scriptional switch may be attributable to the CMG cells having acquired the cardiomyocyte phenotype. The ventricular cardiomyocytes in vivo mainly expressed α 1A and α 1B , and expressed a low level of α 1D receptor. The temporal changes in expression of α 1 adrenergic receptor subtypes in CMG cells are very similar to the postnatal changes observed in neonatal rat heart (Stewart et al., 1994; Rokosh et al., 1996) . ERK1/2 was activated by phenylephrine, an α 1 stimulant, within as little as 5 min, and the activation peaked at 10 min. The phenylephrine-induced phosphorylation was completely inhibited by prazosin (Figure 5b) . Phenylephrine increased the cell area and perimeter of the CMG cardiomyocytes (Figure 5c ). These findings indicated that CMG cells express functionally active α 1 -adrenergic receptors (Hakuno et al., 2002) .
Expression and function of β 1 -and β 2 -adrenergic receptors in CMG cells
The cardiomyocytes of the mammalian hearts express both β 1 and β 2 -adrenergic receptors, the β 1 receptor being the predominant subtype (approximately 75-80% of total β receptors) (Rockman et al., 1997) . CMG cells did not express β 1 and β 2 receptor transcripts before 5-azacytidine exposure, but RT-PCR showed expression of their mRNAs after 1 week (Figure 6a) (Hakuno et al., 2002) . CMG cells expressed β 1 and β 2 mRNA after acquiring the cardiomyocyte phenotype. The temporal pattern of expression of these receptors differed from that of α 1 .
Isoproterenol, a β stimulant, increased the cAMP content of CMG cells, and propranolol completely inhibited the isoproterenol-induced cAMP accumulation (Figures 6b and c) . Isoproterenol was applied to the cells to determine whether it would increase the spontaneous beating rate (Table 2) , and the results showed that it increased it significantly to 48% over the rate in the control cells (Hakuno et al., 2002) . Preincubation with propranolol (non-selective β blocker), CGP20712A (β 1 -selective blocker) strongly reduced the isoproterenol-induced increase in beating rate, and preincubation with ICI118551 (β 2 -selective blocker) only slightly decreased the beating rate. The increase in beating rate was similar to that of adult murine cardiomyocytes and ES cell-derived cardiomyocytes.
We also investigated the effect of isoproterenol on the contractile function of CMG cells and found that it increased cell motion distance, %shortening, and contractile velocity. The isoproterenol-induced increase in contractility was almost completely inhibited by both propranolol and CGP20712A. Collectively, these results indicated that the β 1 and β 2 -adenergic receptors expressed in CMG cells are functional, and that the isoproterenol-induced increase in spontaneous beating rate and contractility is mainly mediated by β 1 receptors. The β 1 receptor was the predominant subtype that mediated changes in the beating rate in CMG cells, and the beating rate and the contractility were significantly increased by isoproterenol, and completely inhibited by propranolol and CGP20712A. β 1 -Receptors played a critical role in mediating the isoproterenolinduced signaling in differentiated CMG cells. This expression pattern was consistent with that of cardiomyocytes in vivo.
CMG cells express muscarinic receptor mRNA after 5-azacytidine exposure
Heart rate, conduction velocity, and contractility were negatively regulated by the parasympathetic nervous system in cardiomyocytes, and muscarinic (cholinergic) receptors play an important role in mediating this function. To date, 5 subtypes (M 1 -M 5 ) of muscarinic receptors have been cloned. The expression of the muscarinic receptors is tissue-specific, and cardiomyocytes mainly express M 2 receptors in the mouse and human (Sharma et al., 1997) . The M 1 receptor subtype is also expressed in murine neonatal and adult cardiomyocytes. Figure 7a shows the temporal expression pattern of M 1 and M 2 receptor mRNA. Neither receptor was detected prior to 5-azacytidine exposure. CMG cells began to express these receptors when they acquired the cardiomyocyte phenotype.
M 1 receptors coupled to Gq/G 11 and activated phospholipase C β via Gqα, leading to IP 3 production, CMG cells at 4 weeks after 5-azacytidine exposure were initially exposed to prazosin (10 −6 mol l −1 ) for 30 min to block α 1 -adrenergic receptors. Cells were then preincubated for 20 min with vehicle (PBS), propranolol, CGP20712A, or ICI118551, and then stimulated with isoproterenol. The beating rate was counted 3 min after stimulation. Contractile parameters were analyzed 90 sec after stimulation. Each contractile parameter value was calculated as the mean of 3 randomly selected beats in one cell. PBS was added to the control. Values are means ± SE (n = 100, each). * : p < 0.05 vs. control, * * : p < 0.01 vs. vehicle (isoproterenol only), * * * : p < 0.05 vs. vehicle, ND: not determined.
and M 2 receptors coupled to Gi/G 0 /Gz and activated phospholipase C β via Giβ γ , leading to IP 3 production (Nakamura et al., 1995; Berstein et al., 1992) . Carbachol, an acetylcholine homologue, increased the content of a second messenger, IP 3 (inositol triphosphate), in CMG cells (Figure 7b) , and preincubation with atropine (non-selective muscarinic blocker) and AFDX116 (M 2 -selective blocker) inhibited the carbachol-induced IP 3 production (Figure 7c ). These findings indicated that muscarinic receptors can transduce their signals, and that M 2 receptors play a critical role in this carbachol-induced IP 3 production in CMG cells. This expression pattern is similar to that of cardiomyocytes in vivo.
Significance of expression of adrenergic and muscarinic receptors in CMG cells
Cardiomyocytes in vivo respond to stimulation by both sympathetic and parasympathetic nerves, and such stimulation alters the heart rate, conduction velocity, and contractility, enabling the cells to adapt to rapid changes in systemic oxygen demand. To date, and to our knowledge, ES cells and mesenchymalstem-cell-derived CMG cells are the only possible candidates for regeneration of cardiomyocytes. We have already transplanted these cells into normal adult mouse hearts, and have observed that transplanted cells survived in recipient hearts for at least several weeks. Regenerated cardiomyocytes must express functional adrenergic and muscarinic receptors to be useful for transplantation, and although we did not investigate all signaling pathways and their functions. CMG cells are potential candidates for cardiomyocyte cell transplantation, because they possess such receptors.
Cell transplantation therapy for the treatment of heart failure
We have already transplanted CMG cells into normal adult mouse hearts, and observed that the transplanted cells could survive in the recipient heart for at least several months. Fibroblasts, smooth muscle cells, and skeletal muscle cells were the first cells used for transplantation into scar tissue secondary to experimental myocardial infarction in the heart in vivo. While transplantation of these cells into scar tissue might improve cardiac remodeling or diastolic function, it is unlikely to improve systolic function. recipients must take immunosuppressants, because ES cells are allogeneic. By contrast, since mesenchymal stem cells do not carry any inherent risks of tumor formation and are syngeneic, it is reasonable to use autologous mesenchymal stem cell to treat heart disease. Nevertheless, there is a need to improve both the current methods for identification and culture of mesenchymal stem cells, and for induction of CMG cell differentiation, which are still inefficient and slow. Identification of specific growth factors, cytokines, or extracellular matrix factors that regulate cardiomyocyte differentiation may help to accelerate this process faster and make it more efficient.
In vivo evidence that marrow cells can generate functional cardiac tissues
Recent studies have revealed that bone-marrowderived cells differentiate into various types of cells in vivo. Shimizu et al. reported that smooth-musclelike cells (SMCs) in graft-vs-host arterial lesions could arise from circulating bone-marrow-derived precursors. They used murine aortic transplants to formally identify the source of SMCs in lesions in grafted arteries (Shimizu et al., 2001 ). Allografts in beta-galactosidase transgenic recipients showed that intimal SMCs arose almost exclusively from host cells, and bone-marrow transplantation of betagalactosidase-expressing cells into aortic allograft recipients demonstrated that the intimal cells included those of marrow origin. Kocher et al. (2001) showed that bone marrow from adult humans contains endothelial precursors with phenotypic and functional characteristics of embryonic hemangioblasts and that they can be used to directly induce new blood vessel formation in the infarct-bed (vasculogenesis) and proliferation of preexisting vasculature (angiogenesis) after experimental myocardial infarction. The neoangiogenesis resulted in decreased apoptosis of hypertrophied myocytes in the peri-infarct region, long-term salvage and survival of viable myocardium, reduction in collagen deposition, and sustained improvement in cardiac function.
We also observed that transplanted bone marrow cells differentiated into cardiomyocytes in the recipient heart in vivo (unpublished observation). These findings provided direct evidence that bone marrow cells can regenerate various types of cells in cardiac tissue. We expect cardiac tissues damaged by myocardial infarction or other diseases to be repaired by bone-marrow-derived stem cells in the near future, and the precise mechanism should be investigated to achieve this goal.
